Journal of the Bahrain Medical Society
Year 2023, Volume 35, Issue 1, Pages 64-67
https://doi.org/10.26715/jbms.35_1_8Dana I. Ajlan1*, Rana Al-Ghatam2
1Resident, Department of primary healthcare, Royal Medical Services, Bahrain Defence Force
2Consultant Orthodontist, DDS Orthodontics (Bristol), FDS RCS (Edinburgh), MOrth RCS (Edinburgh), MFD RCS (Ireland), BDS (London), BSc (Boston), Royal Medical Services, Bahrain Defence Force
*Corresponding author:
Dr. Dana I. Ajlan, Resident, Department of primary healthcare, Royal Medical Services, Bahrain Defence Force; Tel: (+973)-36099622; Email:danai@bdfmedical.org
Received date: March 15, 2022; Accepted date: September 12, 2022; Published date: March 31, 2023
For tables and figures, please refer to PDF.
Abstract
Myasthenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction, characterized by weakness of the muscles. Ocular myasthenia gravis is a subtype of disease where weakness of oculomotor muscles usually occurs with the presence of ptosis. MG is considered a rare disease in pediatric age groups. Acetylcholinesterase inhibitors and immune-modifying medications are usually the mainstays of medication. We report here, a case of a 2-year-old that presented with ptosis and was diagnosed as ocular myasthenia gravis. Our case report describes the clinical presentation, diagnostic tests, and treatments followed.
Keywords: Myasthenia gravis, Ocular myasthenia gravis, Pediatric myasthenia gravis, Ptosis